🫁 Generate:Biomedicines - phase 3 trials of a 6 month asthma treatment
💉@who.int call for rapid expansion of access to new WHO-approved tools to drive down infections on World AIDS Day
Read the full stories
www.liverpool.ac.uk/centre-of-ex...
🫁 Generate:Biomedicines - phase 3 trials of a 6 month asthma treatment
💉@who.int call for rapid expansion of access to new WHO-approved tools to drive down infections on World AIDS Day
Read the full stories
www.liverpool.ac.uk/centre-of-ex...
We're excited to announce the speakers for the first of our new workshop series; LA-LINK
Professor Robert Bies - @ubuffalo.bsky.social
Dr. Harshal Hattyangdi - @liverpooluni.bsky.social
Dr. Catia Marzolini - @unil.bsky.social & @unibas.ch
Dr. @fwojara - Gulu University, Uganda
We're excited to announce the speakers for the first of our new workshop series; LA-LINK
Professor Robert Bies - @ubuffalo.bsky.social
Dr. Harshal Hattyangdi - @liverpooluni.bsky.social
Dr. Catia Marzolini - @unil.bsky.social & @unibas.ch
Dr. @fwojara - Gulu University, Uganda
⭐Designing for the long haul: Lessons for safety studies of long-acting therapeutics from pregnancy through childhood
📆4 February 2026
🗣️Dr Adeniyi Olagunju
www.liverpool.ac.uk/centre-of-ex...
⭐Designing for the long haul: Lessons for safety studies of long-acting therapeutics from pregnancy through childhood
📆4 February 2026
🗣️Dr Adeniyi Olagunju
www.liverpool.ac.uk/centre-of-ex...
The international consortium aim to bring long-acting preventatives/treatments to HCV, malaria and TB patients in LMICs, where these diseases have the biggest impact.
Sign up: www.liverpool.ac.uk/centre-of-ex...
@unitaid.bsky.social
The international consortium aim to bring long-acting preventatives/treatments to HCV, malaria and TB patients in LMICs, where these diseases have the biggest impact.
Sign up: www.liverpool.ac.uk/centre-of-ex...
@unitaid.bsky.social
How do we advocate for children and keep them safe?
We are actively working on child safety; to prevent malaria, and to create better pathways for children within long-acting clinical research.
Read how:
www.liverpool.ac.uk/centre-of-ex...
How do we advocate for children and keep them safe?
We are actively working on child safety; to prevent malaria, and to create better pathways for children within long-acting clinical research.
Read how:
www.liverpool.ac.uk/centre-of-ex...
We wrote a blog on hepatitis testing as a global issue
The #LONGEVITYproject, is working on a one-shot-cure for HCV to provide patients in LMICs treatment at diagnosis
www.liverpool.ac.uk/centre-of-ex...
@unitaid.bsky.social
We wrote a blog on hepatitis testing as a global issue
The #LONGEVITYproject, is working on a one-shot-cure for HCV to provide patients in LMICs treatment at diagnosis
www.liverpool.ac.uk/centre-of-ex...
@unitaid.bsky.social
A new quarterly online workshop series from researchers, regulators, manufacturers, patient advocates, funders and more.
⭐Application of pharmacokinetic modelling and simulation for long-acting medicines
📆29 January
✅Registration soon
www.liverpool.ac.uk/centre-of-ex...
A new quarterly online workshop series from researchers, regulators, manufacturers, patient advocates, funders and more.
⭐Application of pharmacokinetic modelling and simulation for long-acting medicines
📆29 January
✅Registration soon
www.liverpool.ac.uk/centre-of-ex...
We were proud to host a collaborative event at the Liver Building, bringing together leaders from industry, academia, NHS, and regulatory bodies to shape the UK’s future long-acting therapeutics strategy.
We were proud to host a collaborative event at the Liver Building, bringing together leaders from industry, academia, NHS, and regulatory bodies to shape the UK’s future long-acting therapeutics strategy.
💉 ADOCIA: once a month diabetes injection
🔬 SanegeneBio and Innovent: six-monthly hypertension injection
🫀 Rona Therapeutics: reduce ApoC3 and triglycerides
Read more:
www.liverpool.ac.uk/centre-of-ex...
💉 ADOCIA: once a month diabetes injection
🔬 SanegeneBio and Innovent: six-monthly hypertension injection
🫀 Rona Therapeutics: reduce ApoC3 and triglycerides
Read more:
www.liverpool.ac.uk/centre-of-ex...
Laxman Cherkupally from @mmv.org delivered the session titled 'Considerations for long-acting injectable microsuspension development - Lessons from an anti-malarial therapy'
Watch here: youtu.be/3PTuh4sfA4g
Laxman Cherkupally from @mmv.org delivered the session titled 'Considerations for long-acting injectable microsuspension development - Lessons from an anti-malarial therapy'
Watch here: youtu.be/3PTuh4sfA4g
Are you keen to make data from published studies count beyond the paper?
PKRxiv is a managed open-access repository and visualization platform for collaborative sharing of anonymised, PK data and associated covariates.
www.liverpool.ac.uk/centre-of-ex...
Are you keen to make data from published studies count beyond the paper?
PKRxiv is a managed open-access repository and visualization platform for collaborative sharing of anonymised, PK data and associated covariates.
www.liverpool.ac.uk/centre-of-ex...
This month's updates:
Long-acting semaglutide - updated global reg status and clinical trials
Lenacapavir - updated reg status
www.liverpool.ac.uk/centre-of-ex...
This month's updates:
Long-acting semaglutide - updated global reg status and clinical trials
Lenacapavir - updated reg status
www.liverpool.ac.uk/centre-of-ex...
It might not be clear how programming helps our goals to save patient lives through long-acting therapeutics, but it's actually a key part of our work.
Find out how in our blog piece:
www.liverpool.ac.uk/centre-of-ex...
It might not be clear how programming helps our goals to save patient lives through long-acting therapeutics, but it's actually a key part of our work.
Find out how in our blog piece:
www.liverpool.ac.uk/centre-of-ex...
📆 Thursday 6 November 2025
⏰ 10am-4pm
🌍 Liverpool, UK
Find the agenda and how to register: www.liverpool.ac.uk/centre-of-ex...
@ukri.org
📆 Thursday 6 November 2025
⏰ 10am-4pm
🌍 Liverpool, UK
Find the agenda and how to register: www.liverpool.ac.uk/centre-of-ex...
@ukri.org
@nhsengland.bsky.social roll out cabotegravir, two monthly HIV PrEP
ViiV show cabotegravir is more acceptable than lenacapavir
FDA approved @tevapharm.bsky.social UZEDY for bipolar I disorder
www.liverpool.ac.uk/centre-of-ex...
@nhsengland.bsky.social roll out cabotegravir, two monthly HIV PrEP
ViiV show cabotegravir is more acceptable than lenacapavir
FDA approved @tevapharm.bsky.social UZEDY for bipolar I disorder
www.liverpool.ac.uk/centre-of-ex...
We update LONGEVITY news, opportunities and global events.
LONGEVITY, funded by @unitaid.bsky.social, is working to create long-acting malaria, TB and HCV medicines for patients in LMICs.
Sign up: www.liverpool.ac.uk/centre-of-ex...
We update LONGEVITY news, opportunities and global events.
LONGEVITY, funded by @unitaid.bsky.social, is working to create long-acting malaria, TB and HCV medicines for patients in LMICs.
Sign up: www.liverpool.ac.uk/centre-of-ex...
If so, we'd like to add you to the list of publications Teoreler was used for: www.liverpool.ac.uk/centre-of-ex...
Email us on [email protected]
If so, we'd like to add you to the list of publications Teoreler was used for: www.liverpool.ac.uk/centre-of-ex...
Email us on [email protected]
Connecting to organisations is a powerful way to find necessary data.
Read more: www.liverpool.ac.uk/centre-of-ex...
@unitaid.bsky.social
Connecting to organisations is a powerful way to find necessary data.
Read more: www.liverpool.ac.uk/centre-of-ex...
@unitaid.bsky.social
The majority of malaria deaths are children under 5 years old. All malaria work is to protect children health.
events.teams.microsoft.com/event/8ad398...
The majority of malaria deaths are children under 5 years old. All malaria work is to protect children health.
events.teams.microsoft.com/event/8ad398...
We're leading the Manufacturing Capability project to create an open resource to show manufacturing capabilities in LMICs:
www.liverpool.ac.uk/centre-of-ex...
@unitaid.bsky.social
We're leading the Manufacturing Capability project to create an open resource to show manufacturing capabilities in LMICs:
www.liverpool.ac.uk/centre-of-ex...
@unitaid.bsky.social
They'll discuss long acting drug delivery systems and the patents / regulatory process.
Find out more about this and other events CELT are at via our event page:
www.liverpool.ac.uk/centre-of-ex...
They'll discuss long acting drug delivery systems and the patents / regulatory process.
Find out more about this and other events CELT are at via our event page:
www.liverpool.ac.uk/centre-of-ex...
Find a link to the full article and other CELT publications: www.liverpool.ac.uk/centre-of-ex...
Find a link to the full article and other CELT publications: www.liverpool.ac.uk/centre-of-ex...
Find out more if you're new to Teoreler, or leave us feedback if you're not, via the link: www.liverpool.ac.uk/centre-of-ex...
Find out more if you're new to Teoreler, or leave us feedback if you're not, via the link: www.liverpool.ac.uk/centre-of-ex...
We've told you why we think patients accessing research that represents them is important. Now we can show you how we're doing it.
www.liverpool.ac.uk/centre-of-ex...
#AccessToInfo #AccessToInfoDay #RightToKnow
We've told you why we think patients accessing research that represents them is important. Now we can show you how we're doing it.
www.liverpool.ac.uk/centre-of-ex...
#AccessToInfo #AccessToInfoDay #RightToKnow
- @unitaid.bsky.social, Clinton Health Access Initiative and Wits RHI: agreement with Dr Reddy's Laboratories to make affordable lenacapavir
- @unaids.org respond to the announcement of making affordable HIV preventatives.
www.liverpool.ac.uk/centre-of-ex...
- @unitaid.bsky.social, Clinton Health Access Initiative and Wits RHI: agreement with Dr Reddy's Laboratories to make affordable lenacapavir
- @unaids.org respond to the announcement of making affordable HIV preventatives.
www.liverpool.ac.uk/centre-of-ex...